4,5-Diethyl-1,2,3-triazol | 39538-72-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4,5-Diethyl-1,2,3-triazol
• 英文别名: 4,5-diethyl-2H-[1,2,3]triazole；4,5-Diethyl-2H-1,2,3-triazole；4,5-diethyl-2H-triazole
• CAS: 39538-72-2
• 化学式: C₆H₁₁N₃
• 分子量: 125.173
• InChiKey: XUHOSAJLEIASKI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES
  申请人：OxaluRx, Inc.

  公开号：US20210052586A1

  公开（公告）日：2021-02-25

  Disclosed herein are compounds and compositions for modulating glycolate oxidase, useful for treating oxalate-related diseases, such as hyperoxaluria, where modulating glycolate oxidase is expected to be therapeutic to a patent in need thereof. Methods of modulating glycolate oxidase activity in a human or animal subject are also provided.

  本文披露了用于调节甘醇酸氧化酶的化合物和组合物，用于治疗与草酸盐相关的疾病，如高草酸尿症，其中调节甘醇酸氧化酶预计对需要治疗的患者具有疗效。还提供了在人类或动物主体中调节甘醇酸氧化酶活性的方法。
• Modulators of ATP-binding cassette transporters
  申请人：Hadida Ruah S. Sara

  公开号：US20070244159A1

  公开（公告）日：2007-10-18

  Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

  本发明的化合物及其药学上可接受的组合物，可用作调节ATP结合盒（“ABC”）转运蛋白或其片段的工具，包括囊性纤维化跨膜传导调节蛋白（“CFTR”）。本发明还涉及使用本发明的化合物治疗ABC转运蛋白介导的疾病的方法。
• Bicyclic And Tricyclic Derivatives As Thrombin Receptor Antagonists
  申请人：Chackalamannil Samuel

  公开号：US20080090830A1

  公开（公告）日：2008-04-17

  Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein represents an optional double bonds the dotted line is optionally a bond or no bonds resulting in a double bond or a single bond, as permitted by the valency requirement and wherein E, A, G M, Het, B, X, R 3 , R 10 , R 11 , R 32 and R 33 are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failures and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.

  具有以下结构的杂环取代的三环化合物，或者该化合物的药用盐或溶剂化合物、异构体或消旋混合物，其中表示一个可选的双键，虚线可以是一个键或无键，从而形成一个双键或一个单键，符合化合价要求，E、A、G、M、Het、B、X、R3、R10、R11、R32和R33在此有定义，其余取代基如规范中所定义，以及含有它们的药物组合物和通过给予该化合物治疗与血栓形成、动脉粥样硬化、再狭窄、高血压、心绞痛、心律失常、心力衰竭和癌症相关的疾病的方法。还声称与其他心血管药物的联合疗法。
• [EN] EZH2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS D'EZH2 ET LEURS UTILISATIONS
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2017184999A1

  公开（公告）日：2017-10-26

  The present disclosure provides compounds of any one of Formulae (I), (II), and (III). The compounds described herein are inhibitors of histone methyltransferases (e.g., enhancer of zeste homolog 1 (EZHl) and enhancer of zeste homolog 2 (EZH2)) and are useful in treating and/or preventing a broad range of diseases (e.g., proliferative diseases). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

  本公开提供了任一式(I)、(II)和(III)中的化合物。本文描述的这些化合物是组蛋白甲基转移酶（例如，增强子of zeste同源物1（EZHl）和增强子of zeste同源物2（EZH2））的抑制剂，并可用于治疗和/或预防广泛范围的疾病（例如，增殖性疾病）。本公开还提供了包括或使用本文描述的化合物的药物组合物、试剂盒、方法和用途。
• Heterocyclic substituted metallocene compounds for olefin polymerization
  申请人：Voskoboynikov Z. Alexander

  公开号：US20050261449A1

  公开（公告）日：2005-11-24

  This invention relates to compounds represented by formula: wherein M is a group 3, 4, 5 or 6 transition, lanthanide, or actinide metal atom; E is an indenyl ligand substituted in any position with at least one aromatic or pseudoaromatic heterocyclic substituent that is bonded to the indenyl ring through a nitrogen or phosphorous ring heteroatom; A is a substituted or unsubstituted cyclopentadienyl, heterocyclopentadienyl, indenyl, heteroindenyl, fluorenyl, or heterofluorenyl ligand, or other mono-anionic ligand, or A may, independently, be E; Y is an optional bridging group; y is zero or one; X are, independently, univalent anionic ligands, and provided that when A is E, and y is one, and Y is bonded to the one position of each indenyl ligand, and per indenyl ligand there is only one aromatic heterocyclic or pseudoaromatic heterocyclic that is bonded to the indenyl ligand.

  本发明涉及以下式表示的化合物： 其中，M是3、4、5或6族过渡金属、镧系金属或锕系金属原子；E是任何位置上至少带有一种芳香或伪芳香杂环取代基的茚基配体，该取代基通过氮或磷杂环原子与茚环相连；A是取代或未取代的环戊二烯基、杂环戊二烯基、茚基、杂茚基、芴基或杂芴基配体，或其他单阴离子配体，或A可以独立地是E；Y是可选的桥接基团；y为零或一；X是独立的一价阴离子配体，且当A为E，y为一，并且Y与每个茚基配体的一位置相连时，每个茚基配体仅与一个芳香杂环或伪芳香杂环相连。